Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

Jan. 6, 2022, 2:39 p.m. EST

GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    Vir Biotechnology Inc. (VIR)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

GlaxoSmithKline PLC /zigman2/quotes/209463850/composite GSK +2.42% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. /zigman2/quotes/214486077/composite VIR -1.55% . The agreement follows Canada's initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases. Sotrovimab was authorized for injection by Health Canada in July 2021 to treat mild to moderate COVID-19 in adults and adolescents 12 years old and older who are at high risk for hospitalization and death. Glaxo's stock slipped 0.1% in afternoon trading and Vir shares eased 0.1%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.39% gained 0.1%.

/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 44.37
+1.05 +2.42%
Volume: 3.63M
May 16, 2022 4:00p
P/E Ratio
16.09
Dividend Yield
4.51%
Market Cap
$108.55 billion
Rev. per Employee
$552,510
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 22.28
-0.35 -1.55%
Volume: 770,105
May 16, 2022 4:00p
P/E Ratio
2.46
Dividend Yield
N/A
Market Cap
$3.00 billion
Rev. per Employee
$5.24M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,008.01
-15.88 -0.39%
Volume: 2.21B
May 16, 2022 5:14p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.